Back to search results

Radiation for Painful Metastases

This study is investigating a type of radiation therapy called EXTERNAL BEAM RADIATION to treat pain caused by cancer that has spread to bones (non-spine bone metastases) or other parts of the body (non-bone metastases). Researchers want to see if increasing the dose of radiation to 40-50 Gy over ten treatments can improve pain relief. They hope that 40-50% of patients with painful non-spinal bone metastases and 35-45% of patients with painful non-bone metastases will experience complete pain relief after one month. You may be able to join if you are 18 or older, have cancer that has spread, an ECOG Performance Status of 3 or less, a pain score of 3 or higher, and a life expectancy of at least six months. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 124 participants. It is evaluating dose escalation of radiation therapy.
What's involved
Participants will receive EXTERNAL BEAM RADIATION therapy, with a minimum of three treatments per week, for a total of ten treatments. Any missed treatments will be made up.
Compensation
Not stated in the trial record.
Follow-up
Safety will be assessed one month after treatment by monitoring for adverse events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05419518

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Recruiting
PHASE2Ages 18+InterventionalTreatment
Rutgers, The State University of New Jersey
~124 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:EXTERNAL BEAM RADIATION

At a glance

Recruiting sites
6 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety as assessed by number of participants experiencing adverse events
Measured over One month

Conditions

Neoplasm Metastases
Metastases, Neoplasm

Explore related trials

Bone NeoplasmMetastasis

Where it's being run

7 sites across 1 states
New Jersey7

Study leadership

  • Matthew P Deek, MD · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey

Who to contact

Matthew P Deek, MD
[email protected]
732-253-3941
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have provided signed informed consent for the trial
Aged ≥18 years at the time of informed consent
Histologic proof of malignancy
Radiologic or histologic evidence of bone metastases or non-bone metastases
Eastern Cooperative Oncology Group (ECOG) Performance Status of ≥3
Pain Score ≥ 3
Life expectancy of six months or more
Willing and able to comply with all aspects of the protocol
A female participant is eligible to participate if she is not pregnant and not breastfeeding
Woman of childbearing potential who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment.

Exclusion

Metastasis from a highly radiosensitive tumor (eg, lymphoma, myeloma, germ cell tumor)
Spinal metastasis
Active compression of spinal cord/cauda equina
Previous RT or SBRT to the same site
\> 3 sites requiring radiation treatment

What this trial measures

  • Safety as assessed by number of participants experiencing adverse eventsOne month

    Number of participants experiencing adverse effects grade three or higher, as defined by Common Terminology Criteria for Adverse Effects version 5.0 (CTCAE v5.0)